2. Academic Validation
  3. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines

Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines

  • Head Neck. 2017 May;39(5):900-907. doi: 10.1002/hed.24699.
Elisabeth Enzenhofer 1,  Lorenz Kadletz 1,  Isabella Stanisz 1,  Ulana Kotowski 1,  Rudolf Seemann 2,  Rainer Schmid 3,  Dietmar Thurnher 1 4,  Gregor Heiduschka 1
Affiliations

Affiliations

  • 1 Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
  • 2 Department of Oral and Maxillofacial Surgery, Medical University of Vienna, Vienna, Austria.
  • 3 Department of Radiotherapy, Medical University of Vienna, Vienna, Austria.
  • 4 Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
PMID: 28170128 DOI: 10.1002/hed.24699
Abstract

Background: Carcinogenesis is determined by various epigenetic events, such as histone deacetylation. The purpose of this study was to investigate the effect of the new histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma (HNSCC) cell lines.

Methods: The cytotoxicity of resminostat and cisplatin on HNSCC cell lines SCC25, CAL27, and FaDu was determined using CCK-8 cell proliferation assay and combination index analysis. Cells were irradiated with 2 to 8 Gray. Apoptosis was measured using flow cytometry and expression of Mcl-1, p-AKT, and Survivin was investigated.

Results: Treatment with resminostat showed a decrease of cell proliferation of HNSCC cell lines. In addition, a synergistic effect with cisplatin as well as with radiation treatment could be observed. Induction of cell death and dose-dependent downregulation of Survivin was evident in all cell lines.

Conclusion: Resminostat is a promising treatment of HNSCC because of its antiproliferative, chemosensitizing, and radiosensitizing effects. © 2017 Wiley Periodicals, Inc. Head Neck 39: 900-907, 2017.

Keywords

chemosensitizer; head and neck squamous cell carcinoma; histone deacetylases; inhibitors; radiosensitizer; survivin.

Figures
Products